Ananda Pharma PLC - Notice of General Meeting and Proposed Delisting
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF

24
ANANDA PHARMA PLC
("Ananda" or the "Company")
Notice of General Meeting and proposed withdrawal from the AQSE Growth Market
Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a
Subject to shareholder approval of the relevant resolutions set out in the Circular (the "Resolutions"), the General Meeting will be held at
A copy of the Circular, which contains full details of the background, reasons and effects of the Proposals, and the accompanying form of proxy, has been posted to shareholders and is available on the Company's investor website https://investors.anandapharma.co.uk/publications.
Any capitalised terms not defined in this announcement shall have the same meaning as those defined in the Circular.
Rationale for the Proposals
Following an extensive review, the Board has concluded that maintaining the Company's admission to trading on the AQSE Growth Market is not in the best interests of the Company and its shareholders at this time. In reaching this conclusion, the Board considered, among other matters, the ongoing costs and regulatory burden of remaining admitted to trading, the limited liquidity in the Company's Ordinary Shares and associated share price volatility, and the Board's view that as a private company the Company will be better placed to access appropriately structured, specialist life sciences capital to support its clinical development programmes. The Board believes that the time and cost savings arising from the Proposals can be redeployed to core research and development activities, thereby better supporting the Company's strategy.
Executive Chairman's statement:
"As you know I have funded Ananda with more than
Our next milestones are receipt of the full readout from the Phase 1 pharmacokinetic study and commencement of the two Phase 2 placebo controlled clinical trials in endometriosis and Chemotherapy Induced Peripheral Neuropathy (CIPN). These are expected to commence in Quarter 1 2026 and we look forward to keeping shareholders updated as we progress.
To be clear, we will continue to operate on the current strategy. The Company is changing its listing status and being re-registered as a private limited company. Further information regarding the delisting is set out in the letter from the Board.
I would like to thank those of you who have invested in Ananda to date. We will be doing our utmost to get you a return.
If any shareholder has a question about this meeting and decision, please ask it here (https://investors.anandapharma.co.uk/link/ejYBmy) and we will respond as soon as possible."
Expected timetable of principal events
|
Publication and posting of this Circular |
24 November 2025 |
|
Latest time and date for receipt of proxy appointments in respect of the General Meeting |
10 December 2025 |
|
General Meeting |
12 December 2025 |
|
Last day of dealings in Ordinary Shares on the AQSE Growth Market should the Resolutions be approved |
21 December 2025 |
|
Cancellation of admission of the Ordinary Shares to trading on the AQSE Growth Market should the Resolutions be approved |
|
|
Expected re-registration as a private company effective should the Resolutions be approved |
before the end of |
For the purposes of
About Ananda Pharma
Ananda Pharma (AQSE: ANA) is a
For more information, please visit our website:
To stay up to date with Ananda's news please follow our social media channels:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn: https://www.linkedin.com/company/anandapharma
· X: https://twitter.com/AnandaPlc
-Ends-
|
ANANDA PHARMA PLC |
+44 (0)7463 686 497 |
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
Finance Director |
|
|
|
|
|
|
|
|
SP ANGEL CORPORATE FINANCE LLP |
|
|
|
|
|
Corporate Finance |
+44 (0)20 3470 0470 |
|
|
|
|
|
|
|
|
|
|
Corporate Broking |
+44 (0)20 3470 0534 |
|
|
Vadim Alexandre@spangel.co.uk |
|
|
|
|
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE